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A report on the second meeting on ‘Genome
Engineering and Synthetic Biology: Tools and
Technologies’, held 28–29 January 2016 in Ghent,
Belgium.simultaneously. The technique is based on the digestionIntroduction
Over 400 scientists met at the end of January 2016 in
the beautiful town of Ghent, Belgium. The well-
organized meeting was the second in a series that aims
to focus on genome engineering and synthetic biology.
Synthetic biology has been a hot topic for a number of
years. The recent development of tools for engineering
utilizing clustered regularly-interspaced short palindromic
repeats (CRISPR) coupled with the CRISPR-associated
(Cas) nuclease (so-called CRISPR/Cas technology), and
their growing applications, are currently revolutionizing
biology. Not surprisingly, during the meeting CRISPR/Cas
outshined all other topics. This led to some speakers ex-
cusing themselves for not talking about CRISPR/Cas tech-
nology. Thus, this Meeting Report will mainly highlight
recent progress in genome engineering.The CRISPR/Cas revolution is gaining speed
Meeting hundreds of enthusiastic scientists working with
CRISPR/Cas technology, it was hard to believe that the
conference was taking place only three years after the
first reports had been published that revealed that the
CRISPR/Cas system can be used as an efficient tool for
genome engineering in higher eukaryotes.
It was a sound decision by the organizers to start the
meeting with a plenary talk by Jin-Soo Kim from the
Seoul National University, Korea. His talk nicelyCorrespondence: holger.puchta@kit.edu
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of the CRISPR/Cas technology, such as detection and
elimination of off-side effects, as well as broadening its
application. He presented a new method, called ‘multi-
plex Digenome-seq’, to profile genome-wide off-target ef-
fect specificities of multiple CRISPR-Cas9 nucleases
of cell-free human genomic DNA, followed by whole-
genome sequencing. Another option for reducing off-
target effects is to tightly control enzyme activity.
Instead of transforming DNA encoding the Cas9 nucle-
ase and the single guide RNA (sgRNA), preassembled
complexes of purified Cas9 protein and sgRNA had been
transfected successfully by the Korean scientists into
cells. Thus, continuous expression of the enzyme, which
would enhance off-target effects over time, can be
avoided. Notably, this approach is not only attractive for
mammalian cells but additionally for crop plants—such
plants never come into contact with transgenic DNA,
but contain small insertions or deletions that are indis-
tinguishable from naturally occurring mutations. Hope-
fully, these plants will not be regarded as genetically
modified organisms (GMOs) around the globe.
Not only in biotechnology, but also in medicine, new
avenues can be taken by applying CRISPR/Cas:
hemophilia A is an X-linked genetic disorder caused by
mutations in the gene encoding the blood coagulation
factor VIII, which are often chromosomal inversions.
Kim’s group are now (or were) able to revert these
chromosomal inversions in induced pluripotent stem
cells (iPSCs) derived from patients. Thus, in the long-
run, CRISPR/Cas-based therapeutic applications will be-
come an option to fight this disease.Understanding the structure and improving the
precision of Cas9
A way to improve the specificity of Cas9 is to redesign
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Jinek, a pioneer in the CRISPR/Cas field, from the Uni-
versity Zürich, Switzerland, gave an overview of the lat-
est results on the crystal structure of Streptococcus
pyogenes Cas9 in complex with an sgRNA and a target
DNA containing a canonical protospacer adjacent motif
(PAM). The structure revealed that the PAM motif re-
sides in a base-paired DNA duplex, indicating a PAM-
dependent target DNA melting and RNA–DNA hybrid
formation. Using this structure, rational engineering of
Cas9 enzymes with improved specificity or novel PAM
sequences is possible.
Benjamin Kleinstiver of Keith Joung’s group from the
Harvard Medical School in Boston, USA, showed exactly
that—he developed SpCas9-HF1, a high-fidelity variant
harboring alterations designed to reduce non-specific DNA
contacts. SpCas9-HF1 retains on-target activities compar-
able to those of wild-type SpCas9. Notably, use of SpCas9-
HF1 rendered nearly all off-target events undetectable.
One does not have to be a prophet to predict that SpCas9-
HF1 will outcompete wild-type Cas9 enzymes, especially
for therapeutic applications. Kleinstiver also used molecu-
lar evolution to modify the PAM of Staphylococcus aureus
Cas9 (SaCas9). A variant was identified that showed robust
genome editing activities at endogenous human target sites
with modified PAMs, thereby increasing the SaCas9 target-
ing range by twofold to fourfold.
CRISPR/Cas-mediated genome engineering is
becoming more versatile
Randal Platt from Feng Zhang’s group of the Board Insti-
tute in Cambridge, USA, reported on how CRISPR/Cas is
revolutionizing mouse genetics. The group has established
Cas9-expressing mice. By using adeno-associated virus-,
lentivirus- or particle-mediated delivery of guide RNA, in-
duction of mutations can be achieved in neurons, immune
cells and endothelial cells. Using these mice, simultaneous
mutations in KRAS, p53 and LKB1 (encoding serine/threo-
nine-protein kinase STK11)—the three most prominent
genes mutated in lung adenocarcinoma—were obtained.
The respective animals developed macroscopic tumors of
adenocarcinoma. This highlights that these Cas9 mice rep-
resent a tremendous improvement in both time and effi-
ciency in obtaining animal models for carcinogenesis, in
comparison with the classical knockout technology.
How far human disease modeling can be taken was
demonstrated by Weizhi Ji from Kunming Biomed Inter-
national, Kunming, China. His group is using synthetic
nucleases to induce mutations in rhesus and cynomolgus
monkeys. He has been able to reproduce different hu-
man disease syndromes by microinjection of plasmids or
RNAs coding for the respective synthetic nucleases.
Thus, monkeys can be used as an important model spe-
cies for studying human diseases and developingtherapeutic strategies. However, this kind of research
brings us closer to the question as to what point, owing
to ethical considerations, the application of the technol-
ogy should be limited.
Epigenome-editing is breaking new ground
Although applications for genome engineering by
CRISPR/Cas were the central focus of the meeting, other
applications of the technology are also extremely prom-
ising. Charles Gersbach from the Duke University,
Durham, USA, summarized the work of his group using
transcription activator-like effectors (TALEs) and
CRISPR/Cas for epigenome editing. A CRISPR-Cas9-
based acetyltransferase, consisting of the nuclease-null
dCas9 protein fused to the catalytic core of the human
acetyltransferase p300, has been constructed by the
group. The idea was that the fusion protein catalyzes
acetylation of histone H3 lysine 27 at its target sites,
leading to robust transcriptional activation of target
genes. Indeed, Gersbach’s group could show that activa-
tion of the gene(s) was highly specific. These results
demonstrate that targeted acetylation of histones can in-
duce transactivation and is a robust tool for manipulat-
ing gene regulation. Furthermore, they showed that
fusions of nuclease-inactive dCas9 to the Krüppel-asso-
ciated box (KRAB) repressor (dCas9-KRAB) can silence
target gene expression. dCas9-KRAB was targeted to the
HS2 enhancer, a distal regulatory element that orches-
trates the expression of multiple globin genes. A highly
specific induction of H3K9 trimethylation (H3K9me3) at
the enhancer, and decreased chromatin accessibility of
both the enhancer and its promoter targets, were de-
tected. These targeted epigenetic modifications of HS2
correlated with the repression of multiple globin genes.
Owing to the ability to multiplex targets, the CRISPR/
Cas system has the potential to redefine complex gene
expression patterns, especially if different dCas9 ortho-
logs are simultaneously applied in a single cell.
Synthetic biology—getting faster, becoming
smaller and pepping up sex lives
Exciting developments were not only reported in relation
to the application of the CRISPR/Cas technology, but also
for other fields of synthetic biology. Emily LeProust, co-
founder of Twist Bioscience, San Francisco, USA, reported
on a new strategy for making DNA synthesis much faster
and cheaper than before. The company has developed a
semiconductor-based synthetic DNA manufacturing
process, featuring a 10,000-well silicon platform. By synthe-
sizing DNA on silicon instead of traditional 96-well plastic
plates, the platform enables cost-effective, rapid, high-
quality and high-throughput synthetic gene production.
The availability of synthetic DNA at a much lower cost
will be a major advance for different fields of synthetic
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The major breakthrough in this area was synthesis and as-
sembly of the one-megabase-pair Mycoplasma mycoides
genome and its transplantation into a M. capricolum re-
cipient cell by Craig Venter and colleagues in 2010. Daniel
Gibson, inventor of the well-known ‘Gibson Assembly’
technique, from the J. Craig Venter Institute in La Jolla,
USA, made a presentation about making this synthetic
genome even smaller. Through identification of individu-
ally deletable regions, by transposon mutagenesis, and pro-
gressively clustering deleted genomic segments, smaller
mycoplasmal genomes were obtained. The project is still
ongoing, but, as a significant part of the original synthetic
genome could already be eliminated, the analysis is obvi-
ously coming closer to its aim of obtaining the smallest
possible genome for a living organism.
Besides synthesizing artificial genomes, synthetic biology
is developing synthetic entities as novel kinds of detectors
and temporally and spatially tightly controllable inducers.
One can combine these modalities to develop novel
signal-integration circuits. Martin Fusssenegger from the
ETH Zürich, Switzerland, talked about the control of
physiological processes by optogenetic devices that might
provide novel treatment opportunities for therapies. His
group has developed an erectile optogenetic stimulator
(EROS), a synthetic designed guanylate cyclase, producing
a blue-light-inducible rush of the second-messenger cyclic
guanosine monophosphate (cGMP) in mammalian cells,
which enables blue-light-dependent penile erection after
illumination in male rats.
Concluding remarks
Without a shadow of doubt, most participants were sur-
prised and excited by the wealth of novel applications of
synthetic biology and genome engineering on show and
left the meeting with the feeling that there will be much
more progress in the near future.
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